VRAX — Virax Biolabs Group Ltd

Nasdaq · Health Care · Life Sciences Tools & Services · CIK 1885827 ·
Last close
$0.23
Market Cap
$1.69M
52W High
$0.53
52W Low
$0.10
ADV30
37,616,001
Next earnings
Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, other test kits under the ViraxClear brands; and rapid and molecular tests for small animal veterinary diagnostics under the ViraxVet brand. It also provides ViraxImmune, a T cell In vitro diagnostic device and wellness mobile application; and service, such as antibody engineering, custom peptides, protein sequencing, vaccine efficacy testing, immunology lab services, kits and reagents. In addition, the company is involved in research and development activities; and provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, corporations, independent laboratories, large hospital systems and public and private institutions, as well as distributor customers. The company operates in the United Kingdom, the United States, and China. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Sep 2025 5,715,015 3,345,464 641,516
Mar 2025 6,426,903 4,228,944 964,750
Sep 2024 9,442,944 7,285,991 1,026,067

Balance + Analyst (yfinance extras)

Retained Earnings
$-26,928,015
Inventory
$54,186
Receivables
$175,697
ST Investments
EBIT TTM
Pretax Income TTM
Interest Exp TTM
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,986
EBITDA
$-5,556,497
Free Cash Flow
$-3,539,977
Enterprise Value
$-1,322,521
Total Cash
$3,437,848
Total Debt
$537,993
Shares Out
7,423,432
Trailing EPS
$-1.22
Book Value
$0.81
ROE
-83.8%
ROA
-48.4%
Div Yield

Annual Trend (SEC EDGAR, last 3y)

Revenues vs Net Income (last 3y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Mar 2025 6,331 -6,162,897 -6,061,247 6,426,903 964,750 -4,563,576
Mar 2024 156,419 -6,106,118 -6,733,537 5,483,969 345,194 -6,247,016
Mar 2023 8,561 -5,732,761 -5,457,494 9,812,416 908,401 -4,179,767

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.24

Peers — same industry

TickerNameMarket CapLastDaily %
BZYR BURZYNSKI RESEARCH INSTITUTE INC $1.45M $0.01
CBIH Cannabis Bioscience International Holdings, Inc. $3.49M $0.00
ISPC iSpecimen Inc. $4.86M $3.38
BUDZ WEED, INC. $5.04M $0.03
CDIO Cardio Diagnostics Holdings, Inc. $5.24M $1.77

News headlines (Yahoo Finance, 1h cache)

Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes
2026-05-26 11:30 · Yahoo
Avalon Advanced Materials and Virax Biolabs Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
2026-05-15 13:00 · Yahoo
Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders
2026-04-14 11:34 · Yahoo
Virax Biolabs Group Limited (VRAX) Upgraded to Buy: Here's Why
2026-01-15 17:00 · Yahoo
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement
2025-12-04 21:05 · Yahoo
Virax Biolabs Group Limited Announces $5 Million Private Placement
2025-12-03 18:53 · Yahoo
BC-Most Active Stocks
2025-12-03 15:30 · Yahoo
Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders
2025-12-03 12:34 · Yahoo
Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes
2025-11-03 13:29 · Yahoo
Virax Biolabs (VRAX) Falls 18% on Lack of Leads
2025-08-27 16:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.